Symeres has entered a collaboration with Ambagon Therapeutics to explore molecular glues for colorectal cancer and other diseases that remain difficult to target. The partnership brings together Symeres’ drug discovery and development capabilities with Ambagon’s expertise in this emerging class of small molecules. The work is expected to deepen understanding of how these compounds could help unlock new approaches against challenging cancer targets.

For Symeres, the deal also strengthens its position as a partner for biotech companies pursuing novel modalities. For Ambagon, it adds additional research support as the company advances its oncology focused pipeline. The announcement reflects continued industry interest in molecular glue science as drug developers look for fresh ways to reach targets that have been hard to address with conventional medicines.